Trial Profile
Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2020
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms AZABACHE
- Sponsors PETHEMA Foundation
- 03 Apr 2020 Status changed from active, no longer recruiting to completed.
- 13 May 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 12 Jun 2018 Planned End Date changed from 1 May 2018 to 1 Dec 2018.